Bavarian's Mpox Vaccine Targets Infectious Disease in Toddlers

Tuesday, 29 October 2024, 07:09

Infectious diseases impact children significantly, prompting Bavarian to expand the label for its mpox vaccine to include toddlers. This initiative supports public health efforts to combat mpox. A Phase II trial has commenced to evaluate the vaccine's efficacy in children aged 2-11.
Pharmaceutical-technology
Bavarian's Mpox Vaccine Targets Infectious Disease in Toddlers

Infectious diseases present serious risks to young children, which is why Bavarian has initiated a Phase II trial for its mpox/smallpox vaccine aimed at children between 2 and 11 years old. This registrational trial is crucial as it seeks to support the vaccine's approval for pediatric use, enhancing our public health arsenal against infectious diseases.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe